Albert, MS, et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 7(3), 270–279.
Auning, E, et al. (2011) Early and presenting symptoms of dementia with Lewy bodies. Dementia & Geriatric Cognitive Disorders 32(3), 202–208.
Benamer, TS, et al. (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Movement Disorders 15(3), 503–510.
Borson, S, et al. (2010) Comorbidity in aging and dementia: scales differ, and the difference matters. American Journal of Geriatric Psychiatry 18(11), 999–1006.
Chiba, Y, et al. (2012) Retrospective survey of prodromal symptoms in dementia with Lewy bodies: comparison with Alzheimer's disease. Dementia Geriatric Cognitive Disorders 33(4), 273–281.
Donaghy, PC, O'Brien, JT and Thomas, AJ (2015) Prodromal dementia with Lewy bodies. Psychological Medicine 45(2), 259–268.
Donaghy, PC, et al. (2018) Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychological Medicine, 1–7 doi: 10.1017/S0033291717003956 [Epub ahead of print].
Dubois, B, et al. (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology 13(6), 614–629.
Ferman, TJ, et al. (2013) Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology 81(23), 2032–2038.
King, E, et al. (2017) Peripheral inflammation in prodromal Alzheimer's and Lewy body dementias. Journal of Neurology Neurosurgery & Psychiatry 89(4), 339–345.
Lloyd, J, et al. (2018) A new visual rating scale for assessing 123I-FP-CIT imaging in dementia with Lewy bodies: development and autopsy validation. Journal of Nuclear Medicine Under Review.
McGee, S (2002) Simplifying likelihood ratios. Journal of General Internal Medicine 17(8), 646–649.
McKeith, I, et al. (2000) Predictive accuracy of clinical diagnostic criteria for dementia with Lewy bodies: a prospective neuropathological validation study. Neurology 54, 1050–1058.
McKeith, I, et al. (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology 6(4), 305–313.
McKeith, I, et al. (2016) Revisiting DLB diagnosis: a consideration of prodromal DLB and of the diagnostic overlap with Alzheimer disease. Journal of Geriatric Psychiatry & Neurology 29(5), 249–253.
McKeith, IG, et al. (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89(1), 88–100.
McKhann, GM, et al. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 7, 263–269.
Mueller, C, et al. (2017) The prognosis of dementia with Lewy bodies. Lancet Neurology 16(5), 390–398.
Nicastro, N, et al. (2017) Added value of combined semi-quantitative and visual [123I]FP-CIT SPECT analyses for the diagnosis of dementia with Lewy bodies. Clinical Nuclear Medicine 42(2), e96–e102.
NICE (2006) Dementia: supporting people with dementia and their carers in health and social care. Clinical Guidelines CG 42.
O'Brien, JT, et al. (2004) Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Archives of Neurology 61(6), 919–925.
O'Brien, JT, et al. (2009) Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. British Journal of Psychiatry 194(1), 34–39.
O'Brien, JT, et al. (2014) Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open 4(7), e005122.
Postuma, RB, et al. (2015) MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders 30(12), 1591–1601.
Seibyl, JP, et al. (2014) Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. Journal of Nuclear Medicine 55(8), 1288–1296.
Thomas, AJ, et al. (2017) Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 88(3), 276–283.
Tiraboschi, P, et al. (2016) (123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with Lewy bodies from other dementias: a comparative study. Annals of Neurology 80(3), 368–378.
Walker, Z, et al. (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. Journal of Neurology, Neurosurgery & Psychiatry 78(11), 1176–1181.
Walker, Z, et al. & DaTSCAN DLB Phase 4 Study Group (2014) Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. British Journal of Psychiatry 206, 145–152.